- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit
![Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit](https://medicaldialogues.in/h-upload/2022/11/23/750x450_191711-hammer.webp)
United States: A federal judge on Wednesday said Botox maker AbbVie's Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics of taking its confidential data to compete with Allergan's anti-wrinkle injections and facial fillers.
U.S. District Judge Eli Richardson in Nashville, Tennessee, ruled that Allergan plausibly alleged that Revance had acquired and used some of its rival’s trade secrets amid a series of new hires from Allergan.
Richardson said Allergan had “presented enough circumstantial evidence” to overcome Revance’s initial bid to dismiss the lawsuit, which was filed in April.
Nashville-based Revance obtained U.S. regulatory approval in 2022 for an anti-wrinkle injectable product it markets as Daxxify. Revance also separately is developing medication that is biologically similar to Allergan’s Botox.
Attorneys for Revance and a representative for the company did not immediately respond to requests for comment on Thursday.
AbbVie also did not immediately respond to a request for comment.
AbbVie acquired Botox, which launched in 2002, through its $63 billion purchase of Allergan. The drug is also approved for chronic migraine headaches and other therapeutic uses, in addition to cosmetic purposes.
Global Botox net revenue for cosmetics was $620 million in the third quarter, and $748 million for therapeutics in the same period, AbbVie reported in October.
Allergan's lawsuit alleged Revance "accelerated" a plan to recruit from Allergan regulatory professionals, in-house lawyers and sales and marketing employees who were knowledgeable about Botox and the company’s popular dermal filler Juvéderm.
The lawsuit said “it would be very challenging (if not impossible) to produce a biosimilar imitating Botox" without Allergan's confidential information.
Revance in seeking dismissal of the lawsuit said Allergan had not shown Revance had access to any of the trade secrets at issue and called the allegations "nonsensical." It said Allergan had “raced to the courthouse” after Revance won additional regulatory clearances to ramp up production of Daxxify.
Revance said in a court filing that Daxxify “represents a significant threat” to Botox.
The case is Allergan Inc v. Revance Therapeutics Inc, U.S. District Court for the Middle District of Tennessee, No. 3:23-cv-00431.
For Allergan: Jennifer Baldocchi and Eric Dittmann of Paul Hastings; and William (Zan) Blue of Constangy, Brooks, Smith & Prophete
For Revance: Katie Molloy, James Boudreau and Gregory Bombard of Greenberg Traurig.
Original news source: https://www.reuters.com/legal/litigation/botox-rival-revance-loses-bid-dismiss-allergan-trade-secrets-lawsuit-2024-01-04/#:~:text=U.S. District Judge Eli Richardson,of new hires from Allergan.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751